PHARMACIE DE LA PALLICE : revenue, balance sheet and financial ratios

PHARMACIE DE LA PALLICE is a French company founded 22 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in LA ROCHELLE (17000), this company of category PME shows in 2020 a revenue of 2.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE DE LA PALLICE (SIREN 450485842)
Indicator 2024 2023 2022 2020 2019 2018 2017 2016 2013 2012
Revenue N/C N/C N/C 2 766 201 € 2 703 478 € 2 690 363 € 2 622 015 € 2 573 144 € 2 644 293 € 2 699 399 €
Net income 292 792 € 362 090 € 240 202 € 150 848 € 132 325 € 155 060 € 191 790 € 181 515 € 97 234 € 63 192 €
EBITDA N/C N/C N/C 246 296 € 216 739 € 233 586 € 301 778 € 298 854 € 187 681 € 135 316 €
Net margin N/C N/C N/C 5.5% 4.9% 5.8% 7.3% 7.1% 3.7% 2.3%

Revenue and income statement

In 2024, PHARMACIE DE LA PALLICE generates positive net income of 293 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2012-2024: 63 k€ -> 293 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

292 792 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 35%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 61%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

34.886%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

60.616%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

20.0%

Solvency indicators evolution
PHARMACIE DE LA PALLICE

Sector positioning

Debt ratio
34.89 2024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Good -6 pts over 3 years

In 2024, the debt ratio of PHARMACIE DE LA PALLICE (34.89) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
60.62% 2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good +9 pts over 3 years

In 2024, the financial autonomy of PHARMACIE DE LA PALLICE (60.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 141.15. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

141.151

Liquidity indicators evolution
PHARMACIE DE LA PALLICE

Sector positioning

Liquidity ratio
141.15 2024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Average +10 pts over 3 years

In 2024, the liquidity ratio of PHARMACIE DE LA PALLICE (141.15) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 88 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 738 days. Excellent situation: suppliers finance 650 days of the operating cycle (retail model).

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

88 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

738 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE DE LA PALLICE

Positioning of PHARMACIE DE LA PALLICE in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of PHARMACIE DE LA PALLICE is estimated at 4 087 592 € (range 2 846 534€ - 6 115 272€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
2846k€ 4087k€ 6115k€
4 087 592 € Range: 2 846 534€ - 6 115 272€
NAF 5 année 2024

Valuation method used

Net Income Multiple
292 792 € × 14.0x = 4 087 593 €
Range: 2 846 535€ - 6 115 273€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE DE LA PALLICE with other companies in the same sector:

Frequently asked questions about PHARMACIE DE LA PALLICE

What is the revenue of PHARMACIE DE LA PALLICE ?

The revenue of PHARMACIE DE LA PALLICE in 2020 is 2.8 M€.

Is PHARMACIE DE LA PALLICE profitable?

Yes, PHARMACIE DE LA PALLICE generated a net profit of 293 k€ in 2024.

Where is the headquarters of PHARMACIE DE LA PALLICE ?

The headquarters of PHARMACIE DE LA PALLICE is located in LA ROCHELLE (17000), in the department Charente-Maritime.

Where to find the tax return of PHARMACIE DE LA PALLICE ?

The tax return of PHARMACIE DE LA PALLICE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE DE LA PALLICE operate?

PHARMACIE DE LA PALLICE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.